You searched for "intracameral"
Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...Periorbital and subconjunctival emphysema - a sign of orbital rim fracture
Background Orbital emphysema is a condition where air is present in orbit or periorbital tissues [1]. It is most commonly caused by trauma leading to orbit fracture, where air from paranasal sinuses is allowed to enter the orbit. The most...Clinical relevance of the anatomic classification of neovascular age-related macular degeneration
The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...Headaches in ophthalmology (part 2)
Ophthalmologists see a large number of patients with headaches or facial pain in the ophthalmic outpatient clinics or in emergency clinics. Over two articles, I will discuss several causes of headaches, ocular manifestations and proposed management and referral options. It...A single intravitreal bevacizumab in the treatment of breast carcinoma related choroidal metastasis
Case report Choroidal metastasis represents a common form of intraocular malignancies occurring in up to 10% of patients with systemic metastasis [1]. The most common primary sites of ocular metastasis are breast carcinoma in women and lung carcinoma in men,...Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion
Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...Running a high-volume nurse led intravitreal service using the Sp.eye device – the Stanley Eye Unit experience
Introduction The vast majority of ophthalmology units utilise allied healthcare professionals (AHPs) to deliver intravitreal injections (IVIs). The Royal College of Ophthalmologists issued a statement 10 years ago advocating the use of non-medical practitioners performing IVIs [1]. The main benefit...What's trending Jun/Jul 2018
#BusyPhillips #photokeratitis #sunglasses Last time, we were in the throes of the Beast from the East. Here in the UK, it’s been a long winter and cold start to spring. The days are longer now, thanks to British Summer Time,...Pituitary tumours: why are they so often missed?
Part 3: Clinical features, assessment and management (see also Part 2, and Part 1) As previously mentioned in this treatise [1] pituitary tumours are common, occur in all age groups and can present with anything from minimal visual symptoms to...
Adjuvant intravitreal dexamethasone implant for persistent CME
In this retrospective, cross-sectional study the authors investigate the efficiency of intravitreal dexamethasone implants (0.7mg) for cystoid macular oedema (CME) persisting, despite immunomodulatory treatment in patients with Behcets’ disease (BD). Twenty-seven eyes of 20 patients (12 males and eight females)...
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
